PHASE-II STUDY OF EDATREXATE IN ADVANCED HEAD AND NECK-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

Authors
KUEBLER JP BENEDETTI J SCHULLER DE ENSLEY J GRUNBERG SM MUIRHEAD MJ RICHERTBOE KE MARSHALL ME
Citation
Jp. Kuebler et al., PHASE-II STUDY OF EDATREXATE IN ADVANCED HEAD AND NECK-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Investigational new drugs, 12(4), 1994, pp. 341-344
Citations number
9
Categorie Soggetti
Pharmacology & Pharmacy",Oncology
Journal title
Investigational new drugs → ACNP
ISSN journal
01676997
Volume
12
Issue
4
Year of publication
1994
Pages
341 - 344
Database
ISI
SICI code
0167-6997(1994)12:4<341:PSOEIA>2.0.ZU;2-A
Abstract
Fifty-two patients with persistent, recurrent and/or metastatic squamo us cell cancer of the head and neck were treated with weekly edatrexat e, 80 mg/m(2). Nine patients had received previous adjuvant or neoaqju vant chemotherapy. Of the 46 eligible patients, two complete responses and one partial response were observed (6%, 95% confidence interval o f 1-18%). The most common toxicities were myelosuppression and mucosit is, but dermatologic toxicity was also observed in 25% of patients. Ed atrexate appears to have limited activity in advanced head and neck ca ncer.